可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 臧益民,樊荣. 加强多学科协作,争取心血管病研究取得新进展[J]. 心脏杂志, 2006, 18(5):483-488.
[2] 李巧汶,邱健. 炎症标记物与冠心病关系的研究进展[J]. 心脏杂志, 2008, 20(3):359-362.
[3] Kolodgie FD, Virmani R, Burke AP, et al. Pathologic assessment of the vulnerable human coronary plaque[J]. Heart, 2004, 90(12):1385-1391.
[4] Arbustini E.Total erythrocyte membrane cholesterol: an innocent new marker or an active player in acute coronary syndromes?[J]. J Am Coll Cardiol, 2007, 49(21):2090-2092.
[5] Lin HL, Xu XS, Lu HX, et al. Pathological mechanisms of erythrocyte-induced vulnerability of atherosclerotic plaques[J]. Med Hypotheses, 2008, 70(1):105-108.
[6] Tziakas DN, Kaski JC, Chalikias GK, et al. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability?[J]. J Am Coll Cardiol, 2007, 49(21):2081-2089.
[7] Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta. Implications for plaque vulnerability[J]. Circulation, 2004, 110(14):2032-2038.
[8] Kolodgie FD, Burke AP, Nakazawa G, et al. Free cholesterol in atherosclerotic plaques: where does it come from?[J]. Curr Opin Lipidol, 2007, 18(5):500-507.
[9] Kolodgie FD, Narula J, Yuan C, et al. Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? [J]. J Am Coll Cardiol, 2007, 49(21):2093-2101.
[10]Lausada NR, Boullón S, Boullón F, et al. Erythrocyte membrane, plasma and atherosclerotic plaque lipid pattern in coronary heart disease[J]. Medicina(B Aires), 2007, 67(5):451-457.
[11]付文波,丁世芳. 他汀类药物对高血压病血管重构作用的研究现状[J]. 心脏杂志, 2006, 18(5):588-590.
[12]汪俊元,王安才. 他汀类药物对血管重构的干预机制[J] . 心脏杂志, 2006, 18(3):356-358.